文献速递术前评估与围术期医学疼痛医学

术中糖皮质激素预防术后恶心呕吐的获益与风险

Benefits versus harm of intraoperative glucocorticoid for postoperative nausea and vomiting prophylaxis.
PubMed 文献 · Br J Anaesth · 2023-05-12

本文基于大型实用试验(n=8478)的二次分析,探讨术中地塞米松8 mg i.v.用于术后恶心呕吐预防对术后6个月手术切口疼痛的影响。结果显示切口疼痛主要结局在用药组增加,但排除术前切口疼痛患者后,慢性术后疼痛特征(强度和神经病理性特征)无差异。因存在混杂因素,需更严谨研究评估术中糖皮质激素对远期术后疼痛的潜在风险。

要点

  • 术中地塞米松8 mg i.v.预防PONV可能增加术后6个月切口疼痛。
  • 排除术前切口疼痛者后,慢性术后疼痛特征无显著差异。
  • 现有证据受混杂因素影响,需更严谨设计的研究验证。

核心结论

  • 术中地塞米松8 mg i.v.用于PONV预防可能与术后6个月手术切口疼痛增加相关,但慢性术后疼痛特征未显示差异,结论需谨慎解读。

研究设计与样本

  • 围术期地塞米松与感染试验(Perioperative Administration of Dexamethasone and Infection trial)的二次分析,样本量n=8478。

主要发现

  • 接受地塞米松8 mg i.v.用于PONV预防的受试者术后6个月手术切口疼痛主要结局增加。
  • 排除术前切口疼痛患者后,有无术中地塞米松在慢性术后疼痛特征(强度和神经病理性特征)上无差异。
  • 原研究中该剂量地塞米松与手术部位感染的不良效应无关。

关键数值与推荐

  • 地塞米松剂量为8 mg i.v.,用于PONV预防。
  • 主要结局为术后6个月手术切口疼痛。
  • 慢性术后疼痛特征评估包括强度和神经病理性特征。

临床怎么用

  • 麻醉科医生在术中使用地塞米松8 mg i.v.预防PONV时,应权衡其对远期切口疼痛的潜在风险。
  • 对术前存在切口疼痛的患者,地塞米松对慢性术后疼痛特征的影响可能不明显。

局限性

  • 为二次分析,存在多个混杂因素,尤其手术细节相关因素。
  • 发现出乎意料,需更严谨设计的研究验证术中糖皮质激素对远期术后疼痛的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intraoperative use of glucocorticoids is effective for postoperative nausea and vomiting prophylaxis and can also provide early postoperative analgesic effects, but the consequences for chronic post-surgical pain are debatable. In a secondary analysis of the large pragmatic Perioperative Administration of Dexamethasone and Infection trial (n=8478), the primary outcome of pain at the surgical wound at 6 months after surgery was increased in subjects receiving dexamethasone 8 mg i.v. for postoperative nausea and vomiting prophylaxis, a dose not associated with the detrimental effect of surgical site infection in the original study. In contrast, a more detailed assessment of chronic post-surgical pain after exclusion of patients with preoperative pain at the surgical site showed no differences with or without intraoperative dexamethasone regarding chronic post-surgical pain characteristics (intensity and neuropathic features). Because of several confounding factors especially regarding surgical details, these unexpected findings call for more well-designed studies about the potential risk of intraoperative treatments, such as glucocorticoids, on late post-surgical pain.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Lavand'homme P, Kehlet H. Benefits versus harm of intraoperative glucocorticoid for postoperative nausea and vomiting prophylaxis. Br J Anaesth. 2023. PMID: 37183100. doi:10.1016/j.bja.2023.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。